At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 108 enrolled
Drug / intervention
AK112drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/II Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With Advanced NSCLC
In Brief
A Phase 2 clinical trial evaluating AK112 for Non-small Cell Lung Cancer. Completed, enrolled 108 participants across 1 site.
Detailed Summary
This trial is a Phase Ib/II study. All patients are stage IIIB/C or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 in subjects with advanced NSCLC whose tumors have a programmed cell death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) greater than or equal to 1%.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartMay 2021
First PostedMay 2021
Primary CompletionJun 2024
Study CompletionDec 2025
TodayJul 2026
First PostedMay 25, 2021
Enrollment StartMay 21, 2021
Primary CompletionJun 28, 2024
Study CompletionDec 9, 2025
TodayJul 1, 2026
Enrollment to primary: 3.1 yearsPosted 5.1 years ago
Interventions
AK112drug
Subjects receive AK112 intravenously.